Skip to main content

Advertisement

Springer Nature Link
Log in

Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Ten patients with recurrent malignant primary brain neoplasms were treated with adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2). Nine patients had supratentorial glioma and they received multiple intratumoral instillations of LAK cells through reservoir-catheter system or burrhole. The other patients with disseminated subarachnoid metastases from posterior fossa medulloblastoma received immunotherapy via lumbar subarachnoid route. A partial and transient clinical response was observed in two patients following the therapy, and a cystic transformation of the essentially solid tumor was noted on the CT scans of these two patients. No significant clinical or radiological response to the treatment was observed in the remaining 8 patients. The results of this preliminary study reveal limitations of the regional intratumoral adoptive immunotherapy using currently available techniques and provide sufficient evidence of its effectiveness to warrant further investigations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shimizu K, Okamoto Y, Miyao Y, Yamada M, Ushio Y, Hayakawa T, Ikeda H, Mogagami H: Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2. J Neurosurg 66: 519–521, 1987

    Google Scholar 

  2. Walker MD, Green SB, Byar DP, et al.: Randomized comparisons of radiotherapy and nitrosoureas in the treatment of malignant glioma after surgery. N Engl J Med 303: 1323–1329, 1980

    CAS  PubMed  Google Scholar 

  3. Apuzzo MJ, Mitchell MS: Immunological aspects of intrinsic glial tumors. J Neurosurg 55: 1–18, 1981

    Google Scholar 

  4. Mahaley MS, Gillespie GY: Immunotherapy of patients with glioma: Fact, fancy and future. Prog Exp Tumor Res 28: 118–135, 1984

    Google Scholar 

  5. Cheever MA, Greenberg PD, Fefer A, et al.: Augmentation of the antitumor therapeutic efficacy of long term cultured T-lymphocytes by in vivo administration of purified interleukin-2. J Exp Med 155: 968–980, 1982

    Google Scholar 

  6. Steinbok P, Thomas JPW, Grossman L, Dolman CL: Intratumoral autologous mononuclear cells in the treatment of recurrent glioblastoma multiforme. J Neurooncol 2: 147–151, 1984

    Google Scholar 

  7. Young H, Kaplan A, Regllson W. Immunotherapy with autologous white cell infusions (lymphocytes) in the treatment of recurrent glioblastoma multiforme. A preliminary report. Cancer 40: 1037–1044, 1977

    Google Scholar 

  8. Grimm EA: Human lymphokine activated killer cells (LAK cells) as a potential immunotherapeutic modality. Biochem Biophys Acta 865: 267–279, 1986

    Google Scholar 

  9. Grimm EA, Mazumder A, Zhang HG, et al.: Lymphokine activated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823–1841, 1982

    Google Scholar 

  10. Lotze MT, Grimm EA, Mazumder A, et al.: Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T -cell growth factor. Cancer Res 41: 4420–4425, 1981

    Google Scholar 

  11. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Eng J Med 316: 889–897, 1987

    Google Scholar 

  12. Rosenberg SA: Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. In: Devita VT, Hellman S, Rosenberg SA (eds) Important Advances in Oncology, JB Lippincott, Philadelphia 55–91, 1986

    Google Scholar 

  13. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH: Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70: 175–182, 1989

    Google Scholar 

  14. Ingram M, Jaques S, Freshwater DB, Techy GB, Shelden CH, Helsper JT: Salvage immunotherapy of malignant glioma. Arch Surg 122: 1483–1486, 1987

    Google Scholar 

  15. Jacobs SK, Wilson DJ, Melin G, Parham CW Holcomb B, Kornblith PL, Grimm EA: Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: Clinical and experimental studies. Neurol Res 8: 81–87, 1986

    Google Scholar 

  16. Kitahara T, Watanabe O, Yamaura A, Makino H, Watanabe T, Suzuki G, Okumura K: Establishment of interleukin-2 dependent cytotoxic Tlymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor. J Neurooncol 4: 329–336, 1987

    Google Scholar 

  17. Merchant RE, Grant AJ, Merchant LH, Young HF: Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer (LAK) cells and recombinant interleukin-2. Cancer 62: 665–671, 1988

    Google Scholar 

  18. Yoshida S, Tanaka R, Takai N, Ono K: Local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with malignant brain tumours. Cancer Res 48: 5011–5016, 1988

    Google Scholar 

  19. Jacobs SK, Wilson DJ, Kornblith PL, et al.: Interleukin-2 and autologous lymphokine activated killer cells in the treatment of malignant glioma. Preliminary report. J Neurosurg 64: 743–749, 1986

    Google Scholar 

  20. Jacobs SK, Wilson DJ, Kornblith PL, et al.: In vitro killing of human glioblastoma by interleukin-2 activated autologous lymphocytes. J Neurosurg 64: 114–117, 1986

    Google Scholar 

  21. Takakura K, Miki Y, Kulo O, Ogawa N, Matsutani M, Sana K: Adjuvant immunotherapy for malignant brain tumours. Jpn J Clin Oncol 12: 109–129, 1972

    Google Scholar 

  22. Bhagwati SN: Treatment of glioma with intratumoral instillation of autologous lymphocytes. Child's Nerv Syst 4: 1–3, 1988

    Google Scholar 

  23. Lillehei KO, Dawn MH, Stephen J, McCleary EL, Carol KA: Long term follow up of patients with recurrent malignant gliomas treated with adjuvant immunotherapy. Neurosurgery 28: 16–23, 1991

    Google Scholar 

  24. Grimm EA, Muul LM, Wilson DJ: The differential inhibitory effects exerted by cyclosporin and hydrocortisone on the activation of human cytotoxic lymphocytes by recombinant interleukin-2 versus allospecific CTL. Transplantation 39: 537–540, 1985

    Google Scholar 

  25. Papa MZ, Vetto IT, Ettinghausen SE, et al.: Effects of corticosteroids on the antitumor activity of lymphokine activated killer cells and interleukin-2 in mice. Cancer Res 46: 5618–5623, 1986

    Google Scholar 

  26. Vetto JT, Papa MZ, Lotze MT, et al.: Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J Clin Oncol 5: 496–503, 1987

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Tata Memorial Hospital, Bombay, India

    Suresh K. Sankhla

  2. Institute of Medical Sciences, Bombay Hospital, Tata Memorial Hospital, Bombay, India

    J. S. Nadkarni

  3. Immuno Biochem Laboratory, Division of Laboratory Medicine, Tata Memorial Hospital, Bombay, India

    S. N. Bhagwati

Authors
  1. Suresh K. Sankhla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. S. Nadkarni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. N. Bhagwati
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sankhla, S.K., Nadkarni, J.S. & Bhagwati, S.N. Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J Neuro-Oncol 27, 133–140 (1996). https://doi.org/10.1007/BF00177476

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00177476

Key words

Search

Navigation